{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:36:44Z","timestamp":1788982604565,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T00:00:00Z","timestamp":1291680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s11095-010-0332-2","type":"journal-article","created":{"date-parts":[[2010,12,6]],"date-time":"2010-12-06T19:43:02Z","timestamp":1291664582000},"page":"788-796","source":"Crossref","is-referenced-by-count":34,"title":["Formation of Protein Nano-Matrix Particles with Controlled Surface Architecture for Respiratory Drug Delivery"],"prefix":"10.1007","volume":"28","author":[{"given":"Philip Chi Lip","family":"Kwok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amolnat","family":"Tunsirikongkon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak-Kim","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,7]]},"reference":[{"key":"332_CR1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.colsurfa.2005.10.091","volume":"284\u2013285","author":"H-K Chan","year":"2006","unstructured":"Chan H-K. Dry powder aerosol drug delivery\u2014Opportunities for colloid and surface scientists. Colloids Surf, A. 2006;284\u2013285:50\u20135.","journal-title":"Colloids Surf, A"},{"key":"332_CR2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","volume":"6","author":"JS Patton","year":"2007","unstructured":"Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67\u201374.","journal-title":"Nat Rev Drug Discov"},{"key":"332_CR3","first-page":"219","volume-title":"Protein formulation and delivery","author":"AR Clark","year":"2008","unstructured":"Clark AR, Stevenson CL, Shire SJ. Formulation of proteins for pulmonary delivery. In: McNally EJ, Hastedt JE, editors. Protein formulation and delivery. New York: Informa Healthcare USA; 2008. p. 219\u201354."},{"key":"332_CR4","first-page":"65","volume-title":"Pharmaceutical inhalation aerosol technology","author":"I Gonda","year":"2004","unstructured":"Gonda I. Targeting by deposition. In: Hickey A, editor. Pharmaceutical inhalation aerosol technology. New York: Marcel Dekker; 2004. p. 65\u201388."},{"key":"332_CR5","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/jps.20916","volume":"96","author":"AJ Hickey","year":"2007","unstructured":"Hickey AJ, Mansour HM, Telko MJ, Xu Z, Smyth HDC, Mulder T, et al. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci. 2007;96:1282\u2013301.","journal-title":"J Pharm Sci"},{"key":"332_CR6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1023\/A:1012035113276","volume":"14","author":"H-K Chan","year":"1997","unstructured":"Chan H-K, Clark A, Gonda I, Mumenthaler M, Hsu C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm Res. 1997;14:431\u201397.","journal-title":"Pharm Res"},{"key":"332_CR7","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/13543776.13.9.1333","volume":"13","author":"H-K Chan","year":"2003","unstructured":"Chan H-K. Inhalation drug delivery devices and emerging technologies. Expert Opin Ther Pat. 2003;13:1333\u201343.","journal-title":"Expert Opin Ther Pat"},{"key":"332_CR8","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/jps.21195","volume":"97","author":"H Adi","year":"2008","unstructured":"Adi H, Traini D, Chan H-K, Young PM. The influence of drug morphology on the aerosolisation efficiency of dry powder inhaler formulations. J Pharm Sci. 2008;97:2780\u20138.","journal-title":"J Pharm Sci"},{"key":"332_CR9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejps.2008.05.009","volume":"35","author":"S Adi","year":"2008","unstructured":"Adi S, Adi H, Tang P, Traini D, Chan H-K, Young PM. Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur J Pharm Sci. 2008;35:12\u20138.","journal-title":"Eur J Pharm Sci"},{"key":"332_CR10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1023\/A:1013082531394","volume":"18","author":"NYK Chew","year":"2001","unstructured":"Chew NYK, Chan H-K. Use of solid corrugated particles enhance powder aerosol performance. Pharm Res. 2001;18:1570\u20137.","journal-title":"Pharm Res"},{"key":"332_CR11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11095-004-9020-4","volume":"22","author":"NYK Chew","year":"2005","unstructured":"Chew NYK, Tang P, Chan H-K, Raper JA. How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res. 2005;22:148\u201352.","journal-title":"Pharm Res"},{"key":"332_CR12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/17425247.4.6.607","volume":"4","author":"PGA Rogueda","year":"2007","unstructured":"Rogueda PGA, Traini D. The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert Opin Drug Deliv. 2007;4:607\u201320.","journal-title":"Expert Opin Drug Deliv"},{"key":"332_CR13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0021-8502(86)90035-2","volume":"17","author":"J Heyder","year":"1986","unstructured":"Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005\u201315\u00a0\u03bcm. J Aerosol Sci. 1986;17:811\u201325.","journal-title":"J Aerosol Sci"},{"key":"332_CR14","doi-asserted-by":"crossref","first-page":"12001","DOI":"10.1073\/pnas.182233999","volume":"99","author":"N Tsapis","year":"2002","unstructured":"Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci. 2002;99:12001\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"332_CR15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijpharm.2007.03.035","volume":"341","author":"K Hadinoto","year":"2007","unstructured":"Hadinoto K, Zhu K, Tan RBH. Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery. Int J Pharm. 2007;341:195\u2013206.","journal-title":"Int J Pharm"},{"key":"332_CR16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2008.02.008","volume":"128","author":"C G\u00f3mez-Gaete","year":"2008","unstructured":"G\u00f3mez-Gaete C, Fattal E, Silva L, Besnard M, Tsapis N. Dexamethasone acetate encapsulation into Trojan particles. J Control Release. 2008;128:41\u20139.","journal-title":"J Control Release"},{"key":"332_CR17","unstructured":"Loebenberg R, Finlay WH, Roa WH, Ely L. Effervescent powders for inhalation. US 2007\/0031490 A1. 2007."},{"key":"332_CR18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ejpb.2006.10.021","volume":"65","author":"L Ely","year":"2007","unstructured":"Ely L, Roa W, Finlay WH, L\u00f6benberg R. Effervescent dry powder for respiratory drug delivery. Eur J Pharm Biopharm. 2007;65:346\u201353.","journal-title":"Eur J Pharm Biopharm"},{"key":"332_CR19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/03639040802149079","volume":"34","author":"S Azarmi","year":"2008","unstructured":"Azarmi S, L\u00f6benberg R, Roa WH, Tai S, Finlay WH. Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles. Drug Dev Ind Pharm. 2008;34:943\u20137.","journal-title":"Drug Dev Ind Pharm"},{"key":"332_CR20","unstructured":"Finlay W, Orszanska H. Respirable dried powder formulation comprising drug loaded nanoparticles. WO 2006\/130943 A1. 2006."},{"key":"332_CR21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijpharm.2006.03.052","volume":"319","author":"S Azarmi","year":"2006","unstructured":"Azarmi S, Tao X, Chen H, Wang Z, Finlay WH, L\u00f6benberg R, et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm. 2006;319:155\u201361.","journal-title":"Int J Pharm"},{"key":"332_CR22","unstructured":"Finlay WH, Roa W, Loebenberg R. Formulation of powder containing nanoparticles for aerosol delivery to the lungs. US 2005\/0019270 A1. 2005."},{"key":"332_CR23","doi-asserted-by":"crossref","first-page":"13614","DOI":"10.1021\/la802405p","volume":"24","author":"MM Bailey","year":"2008","unstructured":"Bailey MM, Gorman EM, Munson EJ, Berkland C. Pure insulin nanoparticle agglomerates for pulmonary delivery. Langmuir. 2008;24:13614\u201320.","journal-title":"Langmuir"},{"key":"332_CR24","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/jps.21630","volume":"98","author":"N El-Gendy","year":"2009","unstructured":"El-Gendy N, Gorman EM, Munson EJ, Berkland C. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci. 2009;98:2731\u201346.","journal-title":"J Pharm Sci"},{"key":"332_CR25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijpharm.2008.10.016","volume":"369","author":"C Plumley","year":"2009","unstructured":"Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson EJ, Berkland C. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm. 2009;369:136\u201343.","journal-title":"Int J Pharm"},{"key":"332_CR26","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s11095-009-9886-2","volume":"26","author":"N El-Gendy","year":"2009","unstructured":"El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009;26:1752\u201363.","journal-title":"Pharm Res"},{"key":"332_CR27","first-page":"819","volume-title":"Respiratory drug delivery 2010","author":"N El-Gendy","year":"2010","unstructured":"El-Gendy N, Berkland C. Combination nanoparticle agglomerates of fluticasone propionate and albuterol sulphate. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Respiratory drug delivery 2010. River Grove: Davis Healthcare International; 2010. p. 819\u201324."},{"key":"332_CR28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1023\/A:1017592817667","volume":"3","author":"F Iskandar","year":"2001","unstructured":"Iskandar F, Lenggoro W, Xia B, Okuyama K. Functional nanostructured silica powders derived from colloidal suspensions by sol spraying. J Nanopart Res. 2001;3:263\u201370.","journal-title":"J Nanopart Res"},{"key":"332_CR29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaerosci.2008.02.002","volume":"39","author":"H Chiou","year":"2008","unstructured":"Chiou H, Chan H-K, Heng D, Prud\u2019homme RK, Raper JA. A novel production method for inhalable cyclosporine A powders by confined liquid impinging jet precipitation. J Aerosol Sci. 2008;39:500\u20139.","journal-title":"J Aerosol Sci"},{"key":"332_CR30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2006.09.022","volume":"331","author":"H Chiou","year":"2007","unstructured":"Chiou H, Li L, Hu T, Chan H-K, Chen J-F, Yun J. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation. Int J Pharm. 2007;331:93\u20138.","journal-title":"Int J Pharm"},{"key":"332_CR31","unstructured":"Glover WJ, Wan E, Yun JS, Chen J. A process for making micro-sized protein particles. WO 2009\/020434 A1. 2009."},{"key":"332_CR32","unstructured":"Berkland CJ, Shi L. Nanoclusters for delivery of therapeutics. US 7651770 B2. 2010."},{"key":"332_CR33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijpharm.2003.09.044","volume":"269","author":"J-F Chen","year":"2004","unstructured":"Chen J-F, Zhou M-Y, Shao L, Wang Y-Y, Yun J, Chew NYK, et al. Feasibility of preparing nanodrugs by high-gravity reactive precipitation. Int J Pharm. 2004;269:267\u201374.","journal-title":"Int J Pharm"},{"key":"332_CR34","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/jps.21026","volume":"97","author":"T Hu","year":"2008","unstructured":"Hu T, Chiou H, Chan H-K, Chen J-F, Yun J. Preparation of inhalable salbutamol sulphate using reactive high gravity controlled precipitation. J Pharm Sci. 2008;97:944\u20139.","journal-title":"J Pharm Sci"},{"key":"332_CR35","unstructured":"Instruction Manual ULTRA plus Field Emission Scanning Electron Microscope, Carl Zeiss NTS GmBH, Oberkochen, Germany, 2008."},{"key":"332_CR36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejps.2010.02.004","volume":"40","author":"M Kumon","year":"2010","unstructured":"Kumon M, Kwok PCL, Adi H, Heng D, Chan H-K. Can low-dose combination products for inhalation be formulated in single crystalline particles? Eur J Pharm Sci. 2010;40:16\u201324.","journal-title":"Eur J Pharm Sci"},{"key":"332_CR37","unstructured":"British Pharmacopoeia Appendix XII C, Spottiswoode, London, 2010."},{"key":"332_CR38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/jam.1993.6.99","volume":"6","author":"AR Clark","year":"1993","unstructured":"Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers\u2014Implications for in vitro testing. J Aerosol Med. 1993;6:99\u2013110.","journal-title":"J Aerosol Med"},{"key":"332_CR39","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1185\/030079907X219698","volume":"23","author":"M Molimard","year":"2007","unstructured":"Molimard M, Till D, Stenglein S, Singh D, Krummen M. Inhalation devices for long-acting \u03b22-agonists: Efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD. Curr Med Res Opin. 2007;23:2405\u201313.","journal-title":"Curr Med Res Opin"},{"key":"332_CR40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0928-0987(98)00008-6","volume":"7","author":"T Srichana","year":"1998","unstructured":"Srichana T, Martin GP, Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci. 1998;7:73\u201380.","journal-title":"Eur J Pharm Sci"},{"key":"332_CR41","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/jps.21849","volume":"99","author":"C Weiler","year":"2010","unstructured":"Weiler C, Egen M, Trunk M, Langguth P. Force control and powder dispersibility of spray dried particles for inhalation. J Pharm Sci. 2010;99:303\u201316.","journal-title":"J Pharm Sci"},{"key":"332_CR42","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s11095-007-9276-6","volume":"24","author":"D Heng","year":"2007","unstructured":"Heng D, Tang P, Cairney JM, Chan H-K, Cutler DJ, Salama R, et al. Focused-ion-beam milling: a novel approach to probing the interior of particles used for inhalation aerosols. Pharm Res. 2007;24:1608\u201317.","journal-title":"Pharm Res"},{"key":"332_CR43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejps.2010.03.020","volume":"40","author":"H Adi","year":"2010","unstructured":"Adi H, Young PM, Chan H-K, Agus H, Traini D. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci. 2010;40:239\u201347.","journal-title":"Eur J Pharm Sci"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-010-0332-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-010-0332-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-010-0332-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:54:05Z","timestamp":1559368445000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-010-0332-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,7]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1007\/s11095-010-0332-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,7]]}}}